See more : BOCOM Schroders CSI OS China(QDII-LOF)A (164906.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Enzo Biochem, Inc. (ENZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enzo Biochem, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Opawica Explorations Inc. (OPWEF) Income Statement Analysis – Financial Results
- Catcher Technology Co., Ltd. (2474.TW) Income Statement Analysis – Financial Results
- Criteo S.A. (CRTO) Income Statement Analysis – Financial Results
- American Shipping Company ASA (0JE5.L) Income Statement Analysis – Financial Results
- Enbridge Inc. (ENB-PFA.TO) Income Statement Analysis – Financial Results
Enzo Biochem, Inc. (ENZ)
About Enzo Biochem, Inc.
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.91M | 31.06M | 107.07M | 117.73M | 76.02M | 81.17M | 104.71M | 107.80M | 102.77M | 97.60M | 95.95M | 93.71M | 103.08M | 102.03M | 97.08M | 89.57M | 77.80M | 52.91M | 39.83M | 43.40M | 41.64M | 52.77M | 54.02M | 58.41M | 50.03M | 44.30M | 40.40M | 34.90M | 34.50M | 31.70M | 22.80M | 20.00M | 20.50M | 19.80M | 19.40M | 12.10M | 9.10M | 8.70M | 7.30M |
| Cost of Revenue | 17.28M | 19.50M | 65.10M | 64.15M | 52.25M | 57.92M | 60.39M | 59.48M | 57.19M | 54.77M | 54.27M | 54.84M | 55.97M | 53.82M | 52.12M | 53.06M | 40.22M | 23.23M | 16.09M | 14.74M | 13.10M | 11.78M | 10.85M | 17.42M | 14.10M | 14.30M | 13.80M | 13.80M | 13.60M | 12.10M | 9.30M | 6.70M | 6.20M | 21.20M | 5.20M | 3.60M | 1.90M | 1.70M | 1.40M |
| Gross Profit | 14.63M | 11.57M | 41.97M | 53.58M | 23.77M | 23.25M | 44.33M | 48.33M | 45.58M | 42.83M | 41.68M | 38.87M | 47.11M | 48.21M | 44.97M | 36.51M | 37.57M | 29.68M | 23.74M | 28.66M | 28.54M | 40.99M | 43.17M | 40.98M | 35.93M | 30.00M | 26.60M | 21.10M | 20.90M | 19.60M | 13.50M | 13.30M | 14.30M | -1.40M | 14.20M | 8.50M | 7.20M | 7.00M | 5.90M |
| Gross Profit Ratio | 45.86% | 37.24% | 39.20% | 45.51% | 31.27% | 28.64% | 42.33% | 44.83% | 44.35% | 43.88% | 43.44% | 41.48% | 45.70% | 47.25% | 46.32% | 40.76% | 48.30% | 56.09% | 59.60% | 66.03% | 68.53% | 77.67% | 79.92% | 70.17% | 71.81% | 67.72% | 65.84% | 60.46% | 60.58% | 61.83% | 59.21% | 66.50% | 69.76% | -7.07% | 73.20% | 70.25% | 79.12% | 80.46% | 80.82% |
| Research & Development | 2.64M | 3.90M | 3.77M | 3.25M | 4.45M | 3.18M | 3.21M | 2.93M | 3.52M | 3.35M | 3.14M | 3.89M | 6.29M | 7.81M | 9.70M | 9.22M | 8.64M | 9.39M | 7.90M | 8.45M | 8.08M | 8.31M | 6.18M | 6.08M | 5.43M | 4.40M | 4.00M | 3.60M | 3.10M | 2.40M | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 24.36M | 27.20M | 53.71M | 44.91M | 49.69M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -2.63M | 345.00K | 577.00K | 400.00K | 437.00K | 374.00K | 580.00K | 649.00K | 601.00K | 556.00K | 440.00K | 302.00K | 237.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.72M | 27.20M | 53.71M | 44.91M | 42.96M | 44.27M | 44.47M | 44.01M | 43.59M | 41.07M | 41.80M | 43.65M | 51.65M | 48.90M | 52.09M | 45.51M | 43.72M | 41.25M | 35.99M | 30.51M | 32.69M | 28.30M | 28.00M | 25.67M | 23.49M | 20.40M | 19.90M | 16.00M | 17.50M | 17.10M | 10.60M | 16.90M | 12.90M | 0.00 | 15.80M | 12.20M | 9.60M | 9.60M | 4.50M |
| Other Expenses | 0.00 | 380.00K | -1.19M | 6.91M | 488.00K | 382.00K | 168.00K | 125.00K | 122.00K | 95.00K | 194.00K | 5.00K | 5.10M | 4.43M | 3.48M | 5.84M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 0.00 | 500.00K | 300.00K |
| Operating Expenses | 27.00M | 31.11M | 57.47M | 48.16M | 47.41M | 47.44M | 51.37M | 49.71M | 49.45M | 46.70M | 48.01M | 52.04M | 63.05M | 61.14M | 65.28M | 60.57M | 52.36M | 50.64M | 43.89M | 38.96M | 40.77M | 36.61M | 34.18M | 31.75M | 30.84M | 26.70M | 25.80M | 21.40M | 22.40M | 21.30M | 13.90M | 18.40M | 13.60M | 1.20M | 16.30M | 12.50M | 10.10M | 10.10M | 4.80M |
| Cost & Expenses | 44.27M | 50.60M | 122.58M | 112.31M | 99.66M | 105.36M | 111.75M | 109.19M | 106.64M | 101.48M | 102.27M | 106.87M | 119.02M | 114.96M | 117.39M | 113.63M | 92.58M | 73.87M | 59.98M | 53.71M | 53.88M | 48.40M | 45.03M | 49.18M | 44.94M | 41.00M | 39.60M | 35.20M | 36.00M | 33.40M | 23.20M | 25.10M | 19.80M | 22.40M | 21.50M | 16.10M | 12.00M | 11.80M | 6.20M |
| Interest Income | 3.54M | 0.00 | 178.00K | 8.00K | 454.00K | 1.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 581.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 197.00K | 0.00 | 159.00K | 0.00 | 0.00 | 0.00 | 9.78M | 2.58M | 0.00 | 0.00 | 7.14M | 11.52M | 49.99M | 0.00 | 3.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.00M | 0.00 | 0.00 | 2.70M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.27M | 2.68M | 2.83M | 2.65M | 2.78M | 3.04M | 3.13M | 3.60M | 3.84M | 3.79M | 3.97M | 4.61M | 4.48M | 4.47M | 4.27M | 3.46M | 2.15M | 1.19M | 1.12M | 2.33M | 2.36M | 1.81M | 2.15M | 2.25M | 1.93M | 1.90M | 1.90M | 1.80M | 1.80M | 1.80M | 1.50M | 1.50M | 700.00K | 1.20M | 500.00K | 300.00K | 500.00K | 500.00K | 300.00K |
| EBITDA | -8.35M | -20.94M | -15.01M | 3.35M | -27.59M | -24.16M | -3.91M | 1.09M | -6.56M | -1.21M | -5.73M | -14.29M | -11.46M | -8.35M | -17.99M | -20.02M | -8.75M | -19.78M | -19.03M | -7.97M | -9.87M | 6.18M | 11.14M | 11.48M | 7.01M | 5.20M | 2.70M | 1.50M | 300.00K | 100.00K | 1.10M | -3.60M | 1.40M | -1.40M | -1.60M | -3.70M | -2.40M | -2.60M | 1.40M |
| EBITDA Ratio | -26.16% | -39.01% | -10.23% | 10.64% | -19.78% | 100.00% | 100.00% | 100.00% | 100.00% | -1.87% | 1.26% | -3.02% | 13.14% | -8.38% | -14.50% | -22.99% | -16.50% | -42.48% | -47.78% | -50.63% | -23.70% | 11.71% | 20.63% | 19.66% | 14.01% | 11.74% | 1.98% | -0.86% | 18.26% | -35.65% | -6.14% | -13.00% | 8.78% | 16.67% | -19.59% | -61.16% | -59.34% | -67.82% | -9.59% |
| Operating Income | -9.82M | -24.74M | -15.51M | 9.88M | -23.64M | 78.13M | -12.16M | -3.07M | 47.00M | -1.21M | -10.18M | -18.98M | -40.48M | -12.93M | -22.06M | -24.06M | -14.79M | -20.97M | -20.15M | -10.31M | -12.23M | 4.37M | 8.99M | 9.23M | 5.08M | 3.30M | 800.00K | -300.00K | -1.50M | -1.70M | -400.00K | -5.10M | 700.00K | -2.60M | -2.10M | -4.00M | -2.90M | -3.10M | 1.10M |
| Operating Income Ratio | -30.77% | -79.64% | -14.48% | 8.39% | -31.09% | 96.26% | -11.62% | -2.84% | 45.73% | -1.24% | -10.61% | -20.25% | -39.27% | -12.67% | -22.72% | -26.86% | -19.01% | -39.63% | -50.60% | -23.74% | -29.37% | 8.28% | 16.64% | 15.80% | 10.16% | 7.45% | 1.98% | -0.86% | -4.35% | -5.36% | -1.75% | -25.50% | 3.41% | -13.13% | -10.82% | -33.06% | -31.87% | -35.63% | 15.07% |
| Total Other Income/Expenses | 0.00 | -286.00K | -3.31M | 7.18M | 1.85M | 29.68M | 746.00K | 644.00K | 56.92M | -1.09M | 275.00K | 31.00K | -442.00K | 105.00K | -203.00K | -70.00K | 3.89M | 7.79M | 3.14M | 15.52M | 1.15M | 1.36M | 1.35M | 3.00M | 2.58M | 2.10M | 1.80M | 1.90M | -6.00M | 11.40M | 2.60M | -1.20M | -1.80M | 2.60M | -1.80M | 0.00 | 3.00M | -500.00K | 1.00M |
| Income Before Tax | -9.82M | -25.02M | -18.26M | 7.88M | -28.52M | 2.49M | -11.42M | -2.42M | 46.52M | -2.29M | -9.91M | -18.95M | -40.92M | -12.82M | -22.26M | -23.48M | -10.89M | -13.18M | -17.01M | 5.22M | -11.08M | 5.73M | 10.34M | 12.23M | 7.67M | 5.40M | 2.60M | 1.60M | -7.50M | 9.70M | 2.20M | -6.30M | -1.10M | -2.60M | -3.90M | -4.00M | 100.00K | -3.60M | 2.10M |
| Income Before Tax Ratio | -30.77% | -80.56% | -17.06% | 6.69% | -37.52% | 3.07% | -10.90% | -2.25% | 45.26% | -2.35% | -10.32% | -20.22% | -39.70% | -12.57% | -22.93% | -26.21% | -14.00% | -24.90% | -42.71% | 12.02% | -26.61% | 10.85% | 19.14% | 20.94% | 15.33% | 12.19% | 6.44% | 4.58% | -21.74% | 30.60% | 9.65% | -31.50% | -5.37% | -13.13% | -20.10% | -33.06% | 1.10% | -41.38% | 28.77% |
| Income Tax Expense | 0.00 | 12.30M | 4.32M | 4.45M | 5.37M | 101.27M | -1.10M | 82.00K | 1.23M | -7.00K | 72.00K | -712.00K | -1.65M | 137.00K | -28.00K | -87.00K | -239.00K | 85.00K | -1.34M | 2.21M | -4.85M | 1.88M | 3.42M | 5.42M | 1.04M | -1.10M | -800.00K | 100.00K | 200.00K | 4.10M | -2.90M | 100.00K | 100.00K | 12.90M | 200.00K | 100.00K | 600.00K | -2.00M | 600.00K |
| Net Income | -26.08M | 20.29M | -22.58M | 3.43M | -33.89M | -98.78M | -10.32M | -2.50M | 45.29M | -2.29M | -9.98M | -18.24M | -39.27M | -12.96M | -22.23M | -23.56M | -10.65M | -13.26M | -15.67M | 3.00M | -6.23M | 3.84M | 6.92M | 6.81M | 6.62M | 6.50M | 3.40M | 1.50M | -7.70M | 5.60M | 5.30M | -6.90M | -600.00K | -10.80M | -4.10M | -4.10M | -3.50M | -1.60M | 1.50M |
| Net Income Ratio | -81.73% | 65.32% | -21.09% | 2.91% | -44.58% | -121.70% | -9.86% | -2.32% | 44.06% | -2.34% | -10.40% | -19.46% | -38.09% | -12.70% | -22.90% | -26.31% | -13.69% | -25.06% | -39.34% | 6.92% | -14.96% | 7.28% | 12.82% | 11.66% | 13.24% | 14.67% | 8.42% | 4.30% | -22.32% | 17.67% | 23.25% | -34.50% | -2.93% | -54.55% | -21.13% | -33.88% | -38.46% | -18.39% | 20.55% |
| EPS | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.09 | -0.22 | -0.05 | 0.98 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.22 | 0.22 | 0.21 | 0.12 | 0.05 | -0.27 | 0.19 | 0.19 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| EPS Diluted | -0.51 | -1.27 | -0.46 | 0.07 | -0.71 | -2.08 | -0.22 | -0.05 | 0.97 | -0.05 | -0.23 | -0.46 | -1.01 | -0.34 | -0.59 | -0.63 | -0.29 | -0.38 | -0.49 | 0.09 | -0.20 | 0.11 | 0.22 | 0.21 | 0.20 | 0.21 | 0.11 | 0.05 | -0.27 | 0.19 | 0.18 | -0.29 | -0.03 | -0.71 | -0.26 | -0.27 | -0.24 | -0.11 | 0.09 |
| Weighted Avg Shares Out | 50.90M | 49.16M | 48.59M | 48.19M | 47.70M | 47.35M | 46.91M | 46.35M | 46.15M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.10M | 31.70M | 32.97M | 31.36M | 31.25M | 30.79M | 30.31M | 29.97M | 29.47M | 28.84M | 29.38M | 28.05M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
| Weighted Avg Shares Out (Dil) | 50.90M | 49.16M | 48.59M | 48.33M | 47.70M | 47.48M | 46.97M | 46.35M | 46.60M | 45.36M | 42.56M | 39.61M | 38.80M | 38.36M | 38.00M | 37.51M | 36.88M | 35.02M | 32.22M | 32.76M | 31.70M | 33.78M | 32.33M | 32.56M | 32.80M | 30.97M | 31.29M | 29.47M | 28.91M | 29.38M | 29.33M | 24.00M | 18.26M | 15.29M | 15.60M | 15.13M | 14.69M | 14.98M | 16.60M |
Bradley L. Radoff Issues Letter to the Independent Directors of Enzo Biochem Regarding Their Unwillingness to Acknowledge or Address Unprecedented Shareholder Unrest
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.5% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to the independent members of the Company’s...
Enzo Biochem Expands GoTestMeNow™ Online Portal to Provide Patients with Direct Access to Private Testing for Sexually Transmitted Infections
GoTestMeNow™ enables individuals to instantly and privately access physician-authorized testing for a broad range of STIs including chlamydia, gonorrhea, syphilis, HIV-1/2, hepatitis and herpes
Bradley L. Radoff Issues Open Letter to Recently-Appointed Independent Directors of Enzo Biochem
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.2% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to Dr. Mary Tagliaferri and Dr. Ian...
Bradley L. Radoff Issues Open Letter to Recently-Appointed Independent Directors of Enzo Biochem
HOUSTON--(BUSINESS WIRE)--Bradley L. Radoff, who together with his affiliates holds approximately 7.2% of the outstanding common shares of Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company"), today issued the following open letter to Dr. Mary Tagliaferri and Dr. Ian...
HAMID ERFANAIN NAMED CHIEF EXECUTIVE OFFICER OF ENZO BIOCHEM TO ACCELERATE EXPANSION AND COMMERCIALIZATION OF KEY DIAGNOSTIC PLATFORMS
Dr. Elazar Rabbani to remain Chairperson of the Board and will assume new role as Chief Scientific Officer
Enzo Biochem, Inc. (ENZ) Management on Q4 2021 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Management on Q4 2021 Results - Earnings Call Transcript
Enzo Biochem Clocks 27% Revenue Growth In Q4, Margin Remains Stable
Biosciences and diagnostics company Enzo Biochem Inc (NYSE: ENZ) reported fourth-quarter FY21 revenue growth of 27% year-on-year to $24.8 million. Revenue decreased 24% sequentially.
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
Conference call and live webcast scheduled for today, Tuesday, October 12, 2021 at 8:30 am (ET)
ENZ Stock Increases Over 9% Pre-Market: Why It Happened
The stock price of Enzo Biochem, Inc. (NYSE: ENZ) increased by over 9% pre-market. This is why it happened.
Enzo Biochem Announces Online Service with TrustAssure to Schedule Timely PCR Testing Required for International Travel
Testing will be available through CLX Health's TrustAssure™ Global Testing Platform for international travelers from New York and New Jersey who will need to complete testing immediately prior to travel.
Source: https://incomestatements.info
Category: Stock Reports